Achieve Life Sciences (ACHV) Long-Term Debt Issuances (2016 - 2017)

Achieve Life Sciences' (ACHV) quarterly Long-Term Debt Issuances came in at $20000.0 in Q1 2017, down 60.0% on a QoQ basis from $50000.0 in Q4 2016.

Achieve Life Sciences (ACHV) Long-Term Debt Issuances (2016 - 2017) Analysis & Trends

Achieve Life Sciences (ACHV) has 2 years of Long-Term Debt Issuances data on file, last reported at $20000.0 in Q1 2017.

Quarterly Long-Term Debt Issuances changed N/A year-over-year to $20000.0 in Q1 2017, while the trailing twelve-month figure through Dec 2024 was $70000.0 (changed N/A YoY) and the FY2024 annual result came in at $9.8 million, changed N/A from the prior year.
Long-Term Debt Issuances declined to $20000.0 in Q1 2017, from $50000.0 in the prior quarter.
In the past five years, Long-Term Debt Issuances ranged from a high of $50000.0 in Q4 2016 to a low of $20000.0 in Q1 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-675,522.58
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Achieve Life Sciences	330.88 Mn	330.88 Mn	-	-

Download Data